{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T05:47:38Z","timestamp":1768110458423,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejmech.2024.116707","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T12:18:30Z","timestamp":1721823510000},"page":"116707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease"],"prefix":"10.1016","volume":"276","author":[{"given":"Fatima-Zahra","family":"Chaibi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucile","family":"Brier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Carr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lowiese","family":"Desmarets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Tarricone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Cantrelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danai","family":"Moschidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Herledan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Biela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ikherbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Malessan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Dubuisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Belouzard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Hanoulle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-4538","authenticated-orcid":false,"given":"Benoit","family":"Deprez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6895-276X","authenticated-orcid":false,"given":"Julie","family":"Charton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116707_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2020.131761","article-title":"Advances in developing small molecule SARS 3CLpro inhibitors as potential remedy for corona virus infection","volume":"77","author":"Konwar","year":"2021","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2024.116707_bib2","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1039\/D2MD00344A","article-title":"Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020","volume":"14","author":"Chen","year":"2022","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib4","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116707_bib5","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1021\/acs.jmedchem.1c00665","article-title":"3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents","volume":"24","author":"Konno","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science."},{"key":"10.1016\/j.ejmech.2024.116707_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate covid-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116707_bib8","article-title":"Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial","volume":"67","author":"Zhan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejmech.2024.116707_bib9","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of di- and trihaloacetamides as covalent SARS-CoV-2 main protease inhibitors with high target specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116707_bib10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116707_bib11","doi-asserted-by":"crossref","first-page":"9376","DOI":"10.1021\/acs.jmedchem.2c00636","article-title":"Small-Molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure-activity relationships, antiviral activity, and X-ray structure determination","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib12","doi-asserted-by":"crossref","first-page":"16902","DOI":"10.1021\/acs.jmedchem.2c01716","article-title":"Discovery and crystallographic studies of nonpeptidic piperazine derivatives as covalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib13","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116707_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115186","article-title":"Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses","volume":"250","author":"Brier","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115721","article-title":"Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19","volume":"260","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116707_bib16","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1021\/acs.jmedchem.3c00818","article-title":"Discovery and mechanism study of SARS-CoV-2 3C-like protease inhibitors with a new reactive group","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib17","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","article-title":"Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CLpro)","volume":"65","author":"Han","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib18","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1021\/acs.jmedchem.1c00509","article-title":"Expedited approach toward the rational design of noncovalent SARS-CoV-2 main protease inhibitors","volume":"65","author":"Kitamura","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acsmedchemlett.1c00326","article-title":"Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low-nanomolar antiviral potency","volume":"12","author":"Zhang","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116707_bib20","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses","volume":"144","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116707_bib21","doi-asserted-by":"crossref","first-page":"25428","DOI":"10.1002\/anie.202109965","article-title":"NMR spectroscopy of the main protease of SARS-CoV-2 and fragment-based screening identify three protein hotspots and an antiviral fragment","volume":"60","author":"Cantrelle","year":"2021","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2024.116707_bib22","doi-asserted-by":"crossref","first-page":"13343","DOI":"10.1021\/acs.jmedchem.2c01146","article-title":"Discovery and crystallographic studies of trisubstituted piperazine derivatives as non-covalent SARS-CoV-2 main protease inhibitors with high target specificity and low toxicity","volume":"13","author":"Gao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib23","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116707_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ejmech.2024.116707_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/anie.196203511","article-title":"New methods of preparative organic chemistry IV. Syntheses using heterocyclic amides (azolides)","volume":"1","author":"Staab","year":"1962","journal-title":"Angew. Chem., Int. Ed. Engl."},{"issue":"17","key":"10.1016\/j.ejmech.2024.116707_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2024.116707_bib27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41421-024-00673-0","article-title":"Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor Wu-04","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejmech.2024.116707_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104559","article-title":"Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance","author":"Ip","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2024.116707_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105814","article-title":"Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains","author":"Bouzidi","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2024.116707_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1140\/epjp\/i2017-11403-3","article-title":"Status of the Crystallography beamlines at synchrotron SOLEIL","volume":"132","author":"Coati","year":"2017","journal-title":"Eur. Phys. J. Plus"},{"key":"10.1016\/j.ejmech.2024.116707_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1107\/S1600577519001267","article-title":"MXCuBE2: the dawn of MXCuBE collaboration","volume":"26","author":"Oscarsson","year":"2019","journal-title":"J. Synchrotron Radiat."},{"key":"10.1016\/j.ejmech.2024.116707_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2024.116707_bib33","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1107\/S2059798317016035","article-title":"CCP4i2: the new graphical user interface to the CCP4 program suite","volume":"74","author":"Potterton","year":"2018","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"10.1016\/j.ejmech.2024.116707_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2024.116707_bib35","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00018-020-03745-y","article-title":"Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release","volume":"78","author":"Eymieux","year":"2021","journal-title":"Cell. Mol. Life Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424005877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424005877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:50:00Z","timestamp":1730739000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424005877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"alternative-id":["S0223523424005877"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116707","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116707"}}